Chronic, recurrent Lymphocytic Leukemia Completed Phase 2 Trials for Sirolimus (DB00877)

Also known as: Recurrent Chronic Lymphocytic Leukemia

IndicationStatusPhase
DBCOND0112002 (Chronic, recurrent Lymphocytic Leukemia)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01251575Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell TransplantTreatment